Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell
leukemia and lymphoma which led to its incorporation in treatment protocols for these …

Deep remission and prolonged disease-free survival can be achieved with first-line
chemoimmunotherapy (CIT), such as combined fludarabine, cyclophosphamide, and …

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population that
shares certain characteristics including an aberrant myeloid phenotype and the ability to …

Chronic lymphocytic leukemia (CLL) is a malignancy of mature, antigen-experienced B
lymphocytes. Despite great progress recently achieved in the management of CLL, the …

Biologists and clinicians agree that the B-cell receptor influences the behavior of chronic
lymphocytic leukemia, and promising new drugs are aimed at receptor-associated kinases …

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Despite its
indolent clinical course, therapy refractoriness and disease progression still represent an …

Lenalidomide has demonstrated clinical activity in patients with chronic lymphocytic
leukemia (CLL), even though it is not cytotoxic for primary CLL cells in vitro. We examined …

Immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific
antibodies or T-cell engagers, have revolutionized the treatment landscape for various B-cell …

Chronic lymphocytic leukemia (CLL) is characterized by immune defects that contribute to a
high rate of infections and autoimmune cytopenias. Neutrophils are the first line of innate …

Third-generation chimeric antigen receptor T cells (CARTs) for relapsed or refractory (r/r)
chronic lymphocytic leukemia (CLL) may improve efficacy compared to second-generation …